Compare DexCom, Inc. (DXCM) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Illinois Tool Works Inc. — how do they compare? DexCom, Inc. trades at $77.95 (market cap $28.06B), while Illinois Tool Works Inc. trades at $281.65 (market cap $78.08B). The key difference: Illinois Tool Works Inc. is far larger — about 2.8× DexCom, Inc.'s market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ITW | |
|---|---|---|
Market Cap | $28.06B | $78.08B |
Sector | Health | Industrials |
52-Week High | $89.53 | $299.60 |
52-Week Low | $54.84 | $241.07 |
Enterprise Value | $27.03B | $86.41B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
ITW trades at $280.84, up 3.14% with a bullish technical signal and strong earnings beats. The company maintains robust profitability with a 19.32% net margin and 96.88% ROE. Recent Q1 2026 results exceeded expectations with EPS of $2.66, and the upcoming Q2 report on July 28, 2026, is highly anticipated. Dividend payments continue steadily, reinforcing shareholder returns amid modest revenue growth projections.
Outlook remains positive with a consensus price target of $288.25, though risks include construction sector weakness and currency headwinds. The stock's high valuation multiples (P/E 25.2) require sustained earnings growth to justify further upside, while analyst sentiment is mixed with only 21% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
